Among the literature supporting metformin’s role in suppressing inflammation, clinical trials including the Diabetes Prevention Program (DPP) [31] and Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) [32] have provided further evidence of metformin’s role in changing inflammatory biomarker levels among diabetic patients, while other clinical trials, such as the Lantus for C-reactive Protein Reduction in Early Treatment of Type 2 Diabetes (LANCET) [33], have found opposing evidence. This evidence concerns the gene CRP and diabetes mellitus.